Skip to main content
TipRanks
Go Ultimate75% OFF

Aurobindo Pharma Ltd (AUROPHARMA) AI Stock Analysis

7 Followers
IN:AUROPHARMA

Aurobindo Pharma Ltd

(NSE:AUROPHARMA)

Select Model
Rating:69Neutral
Price Target:INR 1,966.00â–²(9.51% Upside)
Action:reiterated
Date:08/23/26

The score is primarily supported by solid financial health (steady growth, conservative leverage, and a strong 2026 free-cash-flow rebound) and constructive technicals (price above key moving averages with positive MACD). This is tempered by weaker valuation support (higher P/E and low dividend yield) and some fundamental watch items such as 2026 margin compression and moderate ROE.

Positive Factors
Steady Revenue and ProfitsRevenue has grown steadily through 2026, while the company retains a 2026 net margin of about 10.4% and EBITDA margin of about 20.4%. This combination indicates a durable operating base that can support reinvestment and earnings resilience.
Negative Factors
Margin CompressionThe sharp decline in gross margin shows that revenue growth is facing pressure at the profitability level. If this compression persists, it could reduce operating leverage, limit earnings conversion, and weaken the company’s ability to compound profits.

Aurobindo Pharma Ltd (AUROPHARMA) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%40%50%60%IN:AUROPHARMA+49.24%INDA-2.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 1.04T
Dividend Yield
0.39%
Average Volume (3M)
52.24K
Price to Earnings (P/E)
26.1
Beta (1Y)
0.63
Revenue Growth
13.53%
EPS Growth
17.04%
Country
India
Employees
29,209
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Aurobindo Pharma Ltd Business Overview & Revenue Model

Company Description

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquid...

Aurobindo Pharma Ltd Financial Statement Overview

Summary

Overall fundamentals are sound: steady revenue growth and solid EBITDA/net margins, a conservatively levered balance sheet with improving debt-to-equity, and a sharp rebound to strong positive free cash flow in 2026. Offsetting this, 2026 margin compression (notably lower gross margin), relatively flat net income across 2024–2026, and only moderate ROE suggest profitability quality needs monitoring.

Income Statement

72Positive

Balance Sheet

78Positive

Cash Flow

70Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue368.68B336.53B317.24B290.02B248.55B234.55B
Gross Profit165.31B131.96B182.40B160.16B132.14B130.06B
EBITDA80.22B72.74B65.78B58.83B37.56B44.33B
Net Income39.90B35.05B34.86B31.73B19.27B26.48B
Balance Sheet
Total Assets617.54B585.02B497.85B450.72B398.90B339.22B
Cash, Cash Equivalents and Short-Term Investments99.78B106.18B82.36B63.25B62.24B45.58B
Total Debt86.30B80.73B82.63B66.48B52.86B32.79B
Total Liabilities223.56B206.19B171.38B152.21B130.38B93.48B
Stockholders Equity394.00B378.91B326.53B298.43B268.40B245.76B
Cash Flow
Free Cash Flow028.27B19.57B-11.27B-3.34B23.12B
Operating Cash Flow055.13B39.25B24.35B23.87B50.16B
Investing Cash Flow0-37.89B-18.76B-42.56B-39.78B-32.12B
Financing Cash Flow0-9.25B1.20B8.00B18.14B-29.69B

Aurobindo Pharma Ltd Technical Analysis

Technical Analysis SentimentPositive
Last Price1795.30

Price Trends

50DMA1693.01Positive
100DMA1642.37Positive
200DMA1491.92Positive

Market Momentum

MACD42.12Negative
RSI62.49Neutral
STOCH56.24Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AUROPHARMA, the sentiment is Positive. The current price of 1795.30 is above the 20-day moving average (MA) of 1723.82, above the 50-day MA of 1693.01, and above the 200-day MA of 1491.92, indicating a bullish trend. The MACD of 42.12 indicates Negative momentum. The RSI at 62.49 is Neutral, neither overbought nor oversold. The STOCH value of 56.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AUROPHARMA.

Aurobindo Pharma Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:AUROPHARMA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:AUROPHARMAIN:AUROPHARMA69NeutralINR 1.04T26.09―0.39%13.53%17.04%
IN:TORNTPHARMIN:TORNTPHARM69NeutralINR 1.76T76.83―0.32%42.06%-3.48%
IN:LUPININ:LUPIN67NeutralINR 914.13B17.68―0.90%24.22%20.24%
IN:SUNPHARMAIN:SUNPHARMA64NeutralINR 4.57T41.24―0.85%12.13%4.94%
IN:DRREDDYIN:DRREDDY62NeutralINR 1.17T41.38―0.58%-3.60%-52.23%
IN:ZYDUSLIFEIN:ZYDUSLIFE61NeutralINR 1.20T28.82―0.08%24.02%-14.86%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

0%20%40%IN:AUROPHARMAIN:DRREDDYIN:LUPININ:SUNPHARMAIN:TORNTPHARMIN:ZYDUSLIFEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:AUROPHARMA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:AUROPHARMAAurobindo Pharma Ltd1795.30605.5250.89%
IN:DRREDDYDr. Reddy's Laboratories Ltd.1390.50173.4714.25%
IN:LUPINLupin Limited2010.0025.691.29%
IN:SUNPHARMASun Pharmaceutical Industries Limited1885.10120.026.80%
IN:TORNTPHARMTorrent Pharmaceuticals Ltd4698.801013.2427.49%
IN:ZYDUSLIFEZydus Lifesciences Limited1195.05269.2829.09%

Aurobindo Pharma Ltd Corporate Events

Aurobindo Pharma Submits Q2 FY27 Earnings Call Transcript

Nov 11, 2026

Aurobindo Pharma Limited is a pharmaceutical company with disclosed business areas including biosimilars, vaccines, peptides, specialties and formulations for the U.S. and Europe. It submitted the transcript of its Q2 FY27 earnings call to the NSE an...

Aurobindo Pharma to Participate in JM Financial Investor Conference

Nov 9, 2026

Aurobindo Pharma Limited is a pharmaceutical company focused on generic medicines and active pharmaceutical ingredients, serving domestic and international markets.Company officials will participate in JM Financial’s India Xchange 2026 Annual India C...

Aurobindo Pharma expands into U.S. contract research with A1 Biochem acquisition

Oct 2, 2026

Aurobindo Pharma, via its wholly owned subsidiary Apitoria Pharma Private Limited, is advancing its strategy to build a contract research footprint by acquiring the Contract Research Services business of A1 Biochem Group. This extends the company’s r...

Aurobindo Pharma Wins USFDA Nod for First Inhaler, Targeting $301 Million Asthma Market

Sep 15, 2026

Aurobindo Pharma has received final approval from the US Food & Drug Administration to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths, the generic equivalent of Teva’s QVAR inhalation aerosol....

Aurobindo Pharma Injects $1 Million into New U.S. R&D Arm After A1 Biochem Deal

Sep 12, 2026

Aurobindo Pharma has taken another step in its acquisition of the A1 Biochem Group by funding a newly formed U.S. subsidiary, A1 Biochem USA Inc, through its step-down subsidiary A1 Biochem Labs (India) Private Limited. The Indian unit has subscribed...

Aurobindo Pharma to Join ICICI Securities Investor Meeting on September 17

Sep 11, 2026

Aurobindo Pharma has informed the stock exchanges that its officials will participate in an investor and analyst group meeting organized by ICICI Securities in Hyderabad on September 17, 2026, between 2:30 PM and 3:30 PM IST. The company emphasized t...

Aurobindo Pharma to Engage Investors at Kotak Healthcare Forum 2026

Sep 11, 2026

Aurobindo Pharma Limited has notified the stock exchanges that its officials will participate in the Kotak Healthcare Forum 2026 in Mumbai on September 18, 2026, with one-on-one and group meetings scheduled throughout the day. The company clarified t...

Aurobindo Pharma’s Lannett Unit Completes Routine U.S. FDA Inspection With Procedural Observations

Aug 24, 2026

Aurobindo Pharma has reported the completion of a routine U.S. FDA inspection at Lannett Company LLC, its wholly owned step-down subsidiary in Seymour, Indiana. The inspection, conducted from August 17 to 21, 2026, resulted in four procedural observa...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 23, 2026